Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2025-03-07 00:00:00 ET · period of report 2025-03-05 · accession 0001628280-25-011410 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-07 | 2025-03-05 | MDGL | Sibold William John | Pres, CEO, Dir | A - Grant | $0.00 | +13.1K | 117.4K | +13% | $0 |
| D | 2025-03-07 | 2025-03-05 | MDGL | Sibold William John | Pres, CEO, Dir | A - Grant | $0.00 | +22.0K | 22.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-05 | A | A | 13,066 | $0.00 | 117,369 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-03-05 | A | A | 22,009 | $0.00 | 22,009 | D | $347.28 · — to 2035-03-05 | 22,009 Common Stock | (F2) The option vests as to 25% of the shares on the first anniversary of the date of grant (March 5, 2026) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |